All In Biotech

Drug Trial Radar · NCT06751329

A Study of DM002 in Patients With Advanced Solid Tumors

A Phase I/IIa, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM002 in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

280

Planned (sponsor's estimate)

Start

Feb 17, 2025

Primary completion

Oct 8, 2027

Study completion Apr 18, 2028

Sponsor

Sponsor type
Industry
First posted
Dec 27, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of study: The study has two parts: Part 1 Dose Escalation and Part 2 Dose Expansion. In Part 1, a few participants will receive the lowest dose of study drug. The study team will make sure it is safe and tolerated before enrolling new participants at a higher dose of study drug. There will be up to six or more dose levels of study drug tested (called cohorts). Which dose you receive will depend on how many participants have taken part in the study before you. The purpose of Part 1 of the study is to evaluate the safety of the study drug at different dose levels, to understand what your body does to the study drug, and to find the best dose of study drug in people who have advanced solid tumor cancers. In Part 2, participants will receive the best dose level that was determined in Part 1 of the study. The purpose of Part 2 of the study is to evaluate the safety of the study drug at the dose level determined in Part 1, to understand what your body does to the study drug, and to see how your cancer responds to the study drug. Participants will: Participants will have 17 or more visits to the study centre. This study has a screening phase of up to 28 days , and a treatment phase with cycles of 21 days each. Participants will also have an End of Treatment (EOT) visit 21 days after the final study drug treatment, and a Follow-up visit 30 days after the EOT visit . Participants will be contacted by telephone every 3 months after the Follow-up visit to check on the wellbeing and record any new anticancer therapy they may have started.

Conditions

  • Ovarian Neoplasms
  • Prostatic Neoplasms
  • Endometrial Neoplasms
  • Colorectal Neoplasms
  • Solid Carcinoma
  • Pancreatic Cancer

Interventions

  • DM002Drug

    An IV infusion of DM002 will be administrated approximately 30-60 min on D1 once Q3W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting Toxicities (DLTs) of DM002Time frame: 12 months
  2. Maximum tolerated dose (MTD) for DM002Time frame: 12 months

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • University of California San Francisco Cancer Center

    San Francisco, California · Recruiting

  • Carolina BioOncology Institute, LLC

    Huntersville, North Carolina · Recruiting

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma · Recruiting

  • The University of Texas, MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Scientia Clinical Research

    Randwick, New South Wales, Australia · Recruiting

  • Cancer Care Wollongong

    Wollongong, New South Wales, Australia · Recruiting

  • Southern Oncology Clinical Research Unit

    Adelaide, South Australia, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.